Checkmate Pharmaceuticals EBIT

Checkmate Pharmaceuticals (CMPI) currently reports a EBIT of $-63M as of March 2022. That compares with $-43M in the prior-year period — down 46.1% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Checkmate Pharmaceuticals's EBIT history and peer comparisons.

Checkmate Pharmaceuticals's EBIT decreased from $-43M to $-63M — a 46.1% year-over-year decrease (period ending March 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Checkmate Pharmaceuticals's EBIT of $-63M is lower than the Healthcare sector average of $22B. That is roughly 100.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Checkmate Pharmaceuticals reported $-63M in EBIT as of March 2022. That compares with $-43M in the prior-year period — down 46.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-63M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Checkmate Pharmaceuticals, and consider following CMPI for alerts when major investors trade the stock.